{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:17:11Z","timestamp":1790745431106,"version":"4.1.0"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2018,12,1]]},"DOI":"10.1001\/jamaoncol.2018.4005","type":"journal-article","created":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T18:31:27Z","timestamp":1539973887000},"page":"1729","source":"Crossref","is-referenced-by-count":127,"title":["Humanized 3F8 Anti-G\n                    <sub>D2<\/sub>\n                    Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma"],"prefix":"10.1001","volume":"4","author":[{"given":"Brian H.","family":"Kushner","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene Y.","family":"Cheung","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakeel","family":"Modak","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M.","family":"Basu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen S.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Kong","family":"Cheung","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"coi180072r1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1471-2407-11-21","article-title":"Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy.","volume":"11","author":"Simon","year":"2011","journal-title":"BMC Cancer"},{"issue":"14","key":"coi180072r2","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.","volume":"363","author":"Yu","year":"2010","journal-title":"N Engl J Med"},{"issue":"26","key":"coi180072r3","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1200\/JCO.2011.41.3807","article-title":"Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.","volume":"30","author":"Cheung","year":"2012","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi180072r4","doi-asserted-by":"publisher","first-page":"e1016704","DOI":"10.1080\/2162402X.2015.1016704","article-title":"Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study.","volume":"4","author":"Kushner","year":"2015","journal-title":"Oncoimmunology"},{"issue":"9","key":"coi180072r5","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1002\/ijc.28851","article-title":"Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma.","volume":"135","author":"Cheung","year":"2014","journal-title":"Int J Cancer"},{"issue":"24","key":"coi180072r6","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1200\/JCO.2000.18.24.4077","article-title":"Phase I study of chimeric human\/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children\u2019s Cancer Group Study.","volume":"18","author":"Ozkaynak","year":"2000","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi180072r7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.4161\/onci.19864","article-title":"Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo.","volume":"1","author":"Cheung","year":"2012","journal-title":"Oncoimmunology"},{"issue":"3","key":"coi180072r8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1517\/14712590802715764","article-title":"Monoclonal antibody therapies for solid tumors.","volume":"9","author":"Tassev","year":"2009","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"coi180072r9","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1182\/blood.V73.7.1936.1936","article-title":"GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma.","volume":"73","author":"Kushner","year":"1989","journal-title":"Blood"},{"issue":"5","key":"coi180072r10","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s00280-014-2575-9","article-title":"Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma.","volume":"74","author":"Desai","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"coi180072r11","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1200\/JCO.2011.37.6236","article-title":"Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor.","volume":"30","author":"Cheung","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi180072r12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/biostatistics\/2.2.203","article-title":"Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials.","volume":"2","author":"Lin","year":"2001","journal-title":"Biostatistics"},{"issue":"9","key":"coi180072r13","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1200\/JCO.2010.28.3317","article-title":"Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study.","volume":"29","author":"Kushner","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"coi180072r14","doi-asserted-by":"publisher","first-page":"e1358331","DOI":"10.1080\/2162402X.2017.1358331","article-title":"Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.","volume":"6","author":"Cheung","year":"2017","journal-title":"Oncoimmunology"},{"issue":"3","key":"coi180072r15","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/(ISSN)1097-0215","article-title":"Disialoganglioside GD2 anti-idiotypic monoclonal antibodies.","volume":"54","author":"Cheung","year":"1993","journal-title":"Int J Cancer"},{"issue":"22","key":"coi180072r16","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1200\/JCO.2016.72.0177","article-title":"Revisions to the International Neuroblastoma Response Criteria: a consensus statement from the National Cancer Institute Clinical Trials Planning Meeting.","volume":"35","author":"Park","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"coi180072r17","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/sj.bjc.6605621","article-title":"Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force.","volume":"102","author":"Matthay","year":"2010","journal-title":"Br J Cancer"},{"issue":"5","key":"coi180072r18","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/1078-0432.CCR-13-1012","article-title":"Phase I trial of a bivalent gangliosides vaccine in combination with \u00df-glucan for high-risk neuroblastoma in second or later remission.","volume":"20","author":"Kushner","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"14","key":"coi180072r19","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1200\/JCO.2013.50.4423","article-title":"Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.","volume":"32","author":"Navid","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi180072r20","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/pbc.25280","article-title":"Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma.","volume":"62","author":"Anghelescu","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"coi180072r21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00262-001-0259-x","article-title":"Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma.","volume":"51","author":"Kremens","year":"2002","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"coi180072r22","doi-asserted-by":"publisher","first-page":"e26732","DOI":"10.1002\/pbc.26732","article-title":"Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: a case series.","volume":"65","author":"Ding","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"coi180072r23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1200\/JCO.2006.10.3564","article-title":"Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children\u2019s Oncology Group.","volume":"27","author":"Gilman","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi180072r24","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00280-015-2955-9","article-title":"Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy.","volume":"77","author":"Marachelian","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"coi180072r25","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1080\/19420862.2015.1130196","article-title":"Pharmacokinetics and pharmacodynamics of ch14.18\/CHO in relapsed\/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2.","volume":"8","author":"Siebert","year":"2016","journal-title":"MAbs"},{"issue":"9","key":"coi180072r26","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1158\/1078-0432.CCR-11-1409","article-title":"New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome.","volume":"18","author":"Cole","year":"2012","journal-title":"Clin Cancer Res"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2703119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,27]],"date-time":"2019-10-27T05:09:15Z","timestamp":1572152955000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.4005"}},"subtitle":["A Phase 1 Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2018,12,1]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.4005","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12,1]]}}}